Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001599298-25-000159
Filing Date
2025-10-20
Accepted
2025-10-20 07:51:24
Documents
63
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q smmt-20250930.htm   iXBRL 10-Q 976117
2 EX-31.1 sum-ex311_20250930xduggan.htm EX-31.1 11712
3 EX-31.2 sum-ex312_20250930xzanganeh.htm EX-31.2 11754
4 EX-31.3 sum-ex313_20250930x10qsoni.htm EX-31.3 11811
5 EX-32.1 sum-ex321_20250930x10q.htm EX-32.1 10991
11 GRAPHIC smmt-20250930_g1.jpg GRAPHIC 18976
12 GRAPHIC smmt-20250930_g2.jpg GRAPHIC 28783
  Complete submission text file 0001599298-25-000159.txt   5596549

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20250930.xsd EX-101.SCH 44033
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT smmt-20250930_cal.xml EX-101.CAL 51413
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20250930_def.xml EX-101.DEF 201122
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20250930_lab.xml EX-101.LAB 549697
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20250930_pre.xml EX-101.PRE 363870
66 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20250930_htm.xml XML 603527
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36866 | Film No.: 251402338
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)